26.01.2009

Pfizer - Wyeth

Pfizer and Wyeth announced that they have entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. The Boards of Directors of both companies have approved the combination.
Acquiring Wyeth would transform Pfizer from a pure pharmaceutical company into a broadly diversified health-care giant, given Wyeth's huge presence in biotech drugs, vaccines, veterinary medicines and consumer health products.